People who were previously housebound with Parkinson’s disease are now able to walk more freely thanks to spinal stimulation treatment.
Browsing: Movement disorders
To mark World Parkinson’s Day, we’re taking the opportunity to look back on some of the research highlights in the field over the last year.
A recently published study has provided evidence that could potentially aid reports into dogs detecting an epileptic seizure odor.
A groundbreaking treatment that delivers a drug directly to the brain may offer hope to restore damaged brain cells in Parkinson’s disease.
Researchers have developed a ‘pacemaker for the brain’, which can monitor and stimulate electric currents, potentially leading to novel treatments in individuals with neurological diseases.
Voyager Therapeutics has announced the first patient dosed in RESTORE-1, a Phase II trial of VY-AADC gene therapy for the treatment of Parkinson’s disease.
After careful evaluation of the ‘Right to Try ‘Act, BrainStorm have announced that it will not make NurOwn® available under this legislation at this time.
Dopamine agonists and prodrugs taken to treat Parkinson’s disease may cause impulse control disorders in over half the patients they are prescribed to.
According to a large study, individuals with Type 2 diabetes may have an increased risk of being diagnosed with Parkinson’s disease later in life.
The National Institute for Health and Care Excellence (NICE) has recommended the use of four out of six disease-modifying therapies in relapsing–remitting multiple sclerosis.